Pharmacodynamics
tumor
TUMOR
A sustained decrease in free soluble CD73 was observed with oleclumab both as monotherapy and in combination with durvalumab in the escalation phase (Fig. Pharmacodynamic effects of oleclumab in the periphery. In the tumor, an ectonucleotidase enzymatic activity assay [Pharmacodynamic effects of oleclumab in tumor tissue. Among 6 patients with matched biopsies who received combination therapy, 4 had increases in CD8+ T cells, 6 had increases in PD-L1+ cells, and 5 had increases in granzyme B+ cells (Fig. Biomarkers in patients who received oleclumab plus durvalumab. The pharmacodynamics of 